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Given the wide range of education programmes 
internationally, what is included within the standard scope of 
practice of Radiation Therapists (RTTs) is highly variable.  
The responsibilities of RTTs are primarily based on historical 
definitions of roles and typically refer to a basic set of 
clinical competencies.  However the professional boundaries 
of RTTs in modern radiotherapy are being challenged and 
redefined.  
Modern radiotherapy cares for a population of increasing age, 
with techniques of increasing complexity. The need for 
improved efficiency, whilst maintaining a high quality service 
has resulted in a demanding work environment for the entire 
multidisciplinary team. As such, RTTs are finding themselves 
taking on increased responsibilities in a wider range of 
clinical tasks.  RTTs today may be involved in complex 
dosimetry and planning, quality assurance, use sophisticated 
image guidance equipment and also assess and triage 
patients for toxicity assessment.  The RTTs involvement in 
education and research activities also continues to grow; 
from simply supporting their colleagues to the actual 
management of clinical trials, as an example.  In an attempt 
to formally recognise this, a number of countries have 
explored the position of Advanced Practice or Specialist 
RTTs.  This concept is more than a change in specific duties, 
but a greater level of understanding and autonomy in their 
work practice. What was once considered advanced is now 
considered standard and as such, the definition of these roles 
is also ever evolving.  What is widely recognised, however, is 
the success of such roles is dependent on a professional 
culture that supports the development of RTTs and an 
education system in place to facilitate this progression. 
Whilst the economic impact of such initiatives is difficult to 
quantify, it has been reported that through role expansion of 
the RTT there has been a decrease in patient wait times with 
improvements in access to care and development of 
innovations in clinical practice. Furthermore, this shift in 
practice has allowed for not just a more efficient use of RTTs 
but has also enabled Radiation Oncologists, Medical Physicists 
and Nursing staff to focus their efforts on development 
within their own disciplines.  
Modern radiotherapy is demanding and as such the role of the 
RTT is dynamic.  As our workforce grows and changes so too 
must our education programmes in order to meet the needs 
of the professional radiotherapy community. 
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New technologies for the radiation treatment of small 
animals allow preclinical studies using orthotopic xenograft 
models with radiochemotherapy that more closely mimic 
clinical studies. We have used an XRad 225Cx small animal 
irradiator/imager to deliver fractionated dose treatment and 
chemotherapy to early-passage orthotopically growing human 
cervix cancer xenografts in immune-deprived mice. This 
model allows assessment of both primary tumor growth and 
metastases occurring in the para-aortic lymph nodes. 
Irradiation treatment was delivered to tumours of 5-8 mm 
diameter growing in the cervix of mice using an 8-beam 
protocol with imaging of the target immediately prior to each 
fraction. The treatment plan allowed for a 1-2 mm margin 
around the imaged tumour target. The radiation treatment 
(15-20 x 2Gy fractions delivered 5 days/wk) was combined 
with weekly cisplatin (4 mg/kg/wk) to match current 
external beam treatment procedures for cervix cancers. 
Tumour growth delay analysis was performed using the 
imaging features of the irradiator to assess tumour size as a 
function of time during and after the treatment. There was 
limited response of the primary tumour to treatment with 
cisplatin alone but significant response to fractionated 
radiation treatment, which was enhanced when combined 
with cisplatin (CRTx). Additional combination treatment with 
either AMD3100, a drug that blocks the interaction of the 
CXCR4 chemokine receptor with its ligand CXCL12, or with 
Hedgehog pathway inhibitors, further enhanced the 
treatment response of the primary tumours.  Lymph nodal 
metastases in the aortic chain were also significantly 
inhibited. No significant short-term toxicities have been 
encountered to date during these studies, in particular there 
is no enhancement of the response of small intestinal stem 
cells as assessed using a GI-tract clonal assay.  
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Nitroglycerin, a nitric oxide donor agent, reduces the 
expression of hypoxia-inducible factor-1α (HIF-1α) and could 
be a normalizer of the tumor microenvironment. Both factors 
are associated with chemo-radio-resistance. Adding 
nitroglycerin to the combination of vinorelbine plus cisplatin 
has been reported to improve the overall survival (OS) of 
Asian patients with stage IIIB/IV non-small cell lung cancer 
(NSCLC) (Yasuda et al. J Clin Oncol. 2006).  Several trials 
tried to confirm that result with contradictory results. A 
Mexican phase 2 trial concluded that the addition of 
nitroglycerin to induction chemotherapy and concurrent 
chemoradiotherapy in patients with locally advanced NSCLC 
has an acceptable toxicity profile. We hypothesize that the 
contradictory results obtained were a consequence of the 
fact that a) we do not know the mechanism of action of 
nitroglycerin and b) the fact we do not have a biomarker to 
select the right patient. We further hypothesize that the 
patient with an hypoxic tumours are more likely to benefit 
form nitroglycerin patch and that nitroglycerin would act as 
inhibitor of oxidative phosphorylation by inhibition of 
complex 1. We tested these two hypothesis respectively with 
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a window of opportunity trial “hypoxia scan-nitroglycerin – 
hypoxia scan” (ClinicalTrials.gov Identifier: NCT01210378) 
and in the lab with a cellular respiration assays measuring 
Oxygen consumption (OCR) and extracellular acidification 
(ECAR) using Seahorse XF96 extracellular Flux analyser.  
Currently 19 patients have received their baseline HX-4 scan 
of which 14 patients received a second nitroglycerin scan as 
well. The median interval between the baseline and 
nitroglycerin scans was 4.5 days (range 2-7 days). 
We found that Nitroglycerin significantly decreases the 
hypoxic fraction in all investigated non-small cell lung cancer 
tumours and metastatic lymph nodes. Our lab work 
demonstrate that nitroglycerin has an inhibitory effect on 
mitochondrial respiration which by decreasing oxygen 
consumption increase the availability of oxygen and decrease 
hypoxia.  
This promising result encourages further investigation of 
nitroglycerin as a radio-sensitizing agent using hypoxia 
imaging as biomarker for selection. 
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Introduction: We have previously shown that αvβ3 integrins 
control radioresistance, hypoxia and angiogenesis and that 
co-expression of FGF-2 and  αvβ3 integrins in the tumors of 
patients treated with exclusive radio-chemotherapy for stage 
III non-small lung carcinoma (NSCLC), was associated with a 
worse local control, suggesting that inhibition of αvβ3 
integrin could induce a radiosensitization of such tumours. 
We designed a phase I trial associating the specific 
αvβ3/αvβ5 integrin inhibitor Cilengitide with radio-
chemotherapy in patients with stage III NSCLC.  
Patients and methods: A standard 3+3 dose escalation design 
was used. Cilengitide was given in continuous infusion 
starting 2 weeks before and then during the whole course of 
the radio-chemotherapy (66 Gy combined with a Platine-
Navelbine regimen), and then at a dose of 2000 mg twice a 
week in association with chemotherapy. Planed Cilengitide 
continuous infusion dose levels were 12, 18, 27 and 40 mg/h. 
PET-FDG and CT scan were performed before and then after 
the first two weeks of Cilengitide administration and then 2 
months after the end of radio-chemotherapy. Patients were 
followed by CT scan. Toxicity for DLT was assessed during 
combined treatment and until 1 month after. Clinical 
response on CT scan and TEP was evaluated according to 
RECIST and PERCIST criteria.  
Results: Fourteen patients were included between March 
2010 and July 2013. Eleven patients were evaluable for DLT. 
No DLT was observed at level 0, 1 and 2. One DLT, a  
tracheo-bronchial fistula was reported at the 40 mg/h dose. 
No relevant adverse event related to Cilengitide (7 grade 1 
and one grade 2) was observed on the whole population. 
Among 11 patients evaluable for efficacy, 9 patients 
presented a partial response and 2 a stable disease. At 12 
months after the end of radio-chemotherapy, 4 patients 
presented a progressive disease. At PET evaluation 2 months 
after radio-chemotherapy, 4 patients had a complete 
response and 4 patients had a partial response. 
Conclusion: Cilengitide given continuously with radio-
chemotherapy was well tolerated and shows encouraging 
clinical results, suggesting that targeting αvβ3 integrin 
continuously during radio-chemotherapy in NSCLC is a 
promising approach to treat this disease.  
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Moulds and Flaps are typically used on superficial skin 
brachytherapy for Planning Target Volume (PTV) up to 5 mm 
depth. In the cases of small and flat PTV, the use of 
superficial skin Applicators is an efficient solution because 
they shield the surrounding healthy tissues. In contrast to 
electrons beams applications (where bolus and specific 
dosimetry is required), treatment planning and delivery is 
simpler. 
 There are radionuclide-based HDR Ir-192 Applicators, as the 
Leipzig (Varian and Elekta) and Valencia (Elekta) ones. The 
Valencia Applicators are a modification of the Leipzig ones 
where a flattering filter has been added. Consequently, 
lateral homogeneity, penumbra, and useful beam are 
improved. However treatment time becomes longer. 
 The electronic HDR brachytherapy surface applicators offer 
an alternative to external beam electrons and HDR 
radionuclide brachytherapy modalities. There are currently 
two systems being used clinically: Xoft Axxent® (iCad) with 
50 kVp which has been in use since 2009 , and Esteya® 
(Elekta) with 69.5 kVp which has been released in 2014. We 
will discuss in this presentation our experience with the 
Esteya Unit, regarding commissioning, QA and clinical 
implementation. 
 Esteya is a new brachytherapy Unit designed to obtain dose 
distributions similar to Valencia App with an X-ray source of 
69.5 kVp. It has an adjustable arm and a set of 
interchangeable circular applicators of different diameters 
(10 mm, 15 mm, 20 mm, 25 mm, and 30 mm). Once overall 
absorbed dose, number of fractions, prescription depth and 
applicator size are selected in the console treatment 
planning system, the system presents automatically the 
treatment time. Compared with the Valencia Applicattors 
there are improvements in penumbra, treatment time, 
gradient on PTV and leakage. 
 The following aspects of commissioning will be discussed on 
this presentation: 
Timer: Reproducibility, accuracy and linearity (combined 
with mA) 
Flatness, symmetry and penumbra: Using radiochromic films 
and high spatial resolution array SRS1000 (PTW, Germany) 
HVL: Diode vs. ionization chamber detectors. Comparison of 
different set-ups 
